Burkholderia Bacteria Produce Multiple Potentially Novel Molecules that Inhibit ESBL E. coli in Urine Samples.

Due to a lack of chemical diversity in the libraries of synthetic compounds, drug development efforts frequently have poor success rates. However, the use of Burkholderia bacteria in the hunt for new antibiotics has recently gained attention. The current investigation sought to identify novel antagonistic compounds by assessing the antibacterial properties of a variety of Burkholderia bacteria.A variety of 24 Burkholderia isolates were chosen from our internal strain collection of environmental sources. Using the agar well diffusion assay, Burkholderia isolates were examined for antibiotic efficacy against a variety of pathogens. Burkholderia isolates with an inhibitory zone diameter of at least 5 mm were deemed active.Antimicrobial activity was detected in only 3 out of 24 strains tested. These findings included the producers of three known Burkholderia antimicrobials: Para Burkholderia ST19, Burkholderia gladioli ST24, and Burkholderia cepacia complex ST36. A taxonomically and geographically varied group of isolates was screened for antagonistic activity against a panel of 49 human pathogens, including E. coli, Klebsiella, and Pseudomonas, in order to investigate Burkholderia's antimicrobial potential.Three isolates inhibited ESBL strains of E. coli. Burkholderia gladioli ST24 was the only strain with activity against 3 ESBL E. coli of the urine sample, which might be due to multiple metabolites acting together.Surprisingly, the strain only exhibited the antimicrobial activity when treated at 37 and 42, not 100. Analysis of variance (ANOVA) revealed no significant differences in antibiotic production among the three bacterial strains (F = 0.55, p = 0.58). Thus, the strains exhibited comparable antibiotic-producing capabilities under the experimental conditions tested. The results of this study confirm and add to the idea that Burkholderia bacteria present attractive opportunities for several possibly novel compounds that inhibit ESBL E. coli in urine samples.